Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenecteplase - Genentech

Drug Profile

Tenecteplase - Genentech

Alternative Names: Metalyse; Recombinant tissue plasminogen activator-Genentech; RG-3625; TNK; TNK-tPA; TNKase

Latest Information Update: 10 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Boehringer Ingelheim; Genentech; Roche Canada
  • Class Blood coagulation factors; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase III Stroke
  • Discontinued Catheter thrombosis; Heart arrest

Most Recent Events

  • 29 Apr 2019 Phase-III clinical trials in Stroke in Canada (IV) (NCT03785678)
  • 29 Apr 2019 Phase-III clinical trials in Stroke in USA (IV)
  • 24 Dec 2018 Genentech plans the phase III TIMELESS trial for Stroke in USA (IV) (NCT03785678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top